Support Education Research
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #846 | January 3, 2020  

2020 Conference Seattle Save the Date


Save the Date:
July 17-19, 2020

The National Patient Education Conference takes place July 17-18-19, 2020, in Bellevue, Washington, on Seattle's Eastside.

To be notified when scholarship applications and general registration open, sign up for the Conference e-Alert.

CONFERENCE E-ALERT

Scleroderma Voice Winter 2019 Cover


Is Your Email Address Current?

Email is a highly cost-efficient way for the Scleroderma Foundation to communicate with its members.  If you don't have an email address on file with the Foundation, or if you recently changed your email address, please contact webmaster@scleroderma.org with your current email address.

Learn about the Foundation's privacy policy and how we protect your personal information, for example: we never give, sell, or rent our mailing lists.  

UPDATE EMAIL

library resources


Resource Organizations

Scleroderma affects many aspects of a person's life.  No one organization or governmental agency can fully address every issue the disease creates.  Googling can produce curious results that can't always be trusted.  To help individuals and families affected by scleroderma navigate the community of organizations that can make a difference in their lives, the Scleroderma Foundation compiled a list of government, research, and other associations, foundations, and societies.  These are organizations known to the Scleroderma Foundation to be reliable and to have expertise in their field of operation.

ORGANIZATIONS

Advocacy Capitol Hill 2018 Gietzen

Amy Gietzen
Capitol Hill Day 2018


National Commission on Scleroderma and Fibrotic Diseases Act of 2019

Learn about the National Commission on Scleroderma and Fibrotic Diseases Act of 2019, it's a bipartisan and budget-neutral bill that, if enacted into law, will coordinate research related to scleroderma and other fibrotic diseases--research already funded by the National Institutes of Health.  The bill exists in both the House (H.R. 3446) and the Senate (S. 2477).

Go to scleroderma.org/advocacy to read the bill and to find letters to your U.S. Representative and Senators asking them to become a cosponsor.  It's easy. Print, sign, scan, and email the letters back to the Foundation, advocacy@scleroderma.org. Or, mail them to Scleroderma Foundation, ATTN: Advocacy, 300 Rosewood Drive, Suite 105, Danvers, MA  01923. All letters are hand-delivered to Capitol Hill.

READ MORE

Clinical Trial Opportunities

ClinicalTrials.gov

Clinical Trials mapYou can track clinical trials for scleroderma, systemic sclerosis (SSc), pulmonary hypertension, and more at ClinicalTrials.gov. This robust website is published and maintained by the National Institutes of Health, U.S. National Library of Medicine. Search options include trials that are recruiting, country, state, and more. States highlighted in red in the map (left) have the most scleroderma-related trials. This concentration in specific states is solely the result of the geographic location of the institutions that focus on scleroderma research.

You can also find information about scleroderma-related clinical trials on scleroderma.org/centers, where designated "Scleroderma Research and Treatment Centers" list the trials taking place in their institutions.

CLINICAL TRIALS

 
QUICK LINKS
 
Advocacy
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Store
Make a Gift
Home
 
SOCIAL MEDIA
 
Facebook
Twitter
Instagram
YouTube
 
 
SPONSORS
 
Diamond National Sponsor

Actelion Plain

 

 
Platinum National Sponsor

Boehringer Ingelheim Plain

 

 
Corporate Sponsors
Bayer National Sponsor

Reata Logo.jpg

United Therapeutics Logo

CSL Behring logo

Corbus Pharmaceuticals Logo

 

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2020 All rights reserved.